Therapeutic Effects of Oral and Topical Curcumin in the Treatment of Eczema

Comparison of the Effectiveness of Oral and Topical Curcumin versus Placebo in Improving Disease Severity, Itching, and Quality of Life in Patients with Mild to Severe Eczema

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250926067366N1

Enrollment

Registered

2025-10-05

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema. Intrinsic (allergic) eczema

Interventions

Intervention 1: Intervention group:1:Oral curcumin: Abureyhan curcumin capsules 500 mg, administered at a dose of 1000 mg per day (two 500 mg capsules). Intervention 2: Intervention group:2:Topical cu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years ?Suffering from mild, moderate, or severe eczema based on Eczema Area and Severity Index Patients who have not previously received any treatment for eczema

Exclusion criteria

Exclusion criteria: Lack of consent to participate in the study Significant organ dysfunction Cutaneous malignancies Generalized eczema Pregnant or breastfeeding women Women of childbearing age who do not use adequate contraception Inability to adhere to treatment or attend regular follow-up visits

Design outcomes

Primary

Measure	Time frame
Eczema severity. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Eczema Area and Severity Index (EASI) or Scoring Atopic Dermatitis (SCORAD).;Pruritus severity. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Visual Analog Scale (VAS).;Skin-related quality of life. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Dermatologic Life Quality Index (DLQI).	—

Measure

Time frame

Eczema severity. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Eczema Area and Severity Index (EASI) or Scoring Atopic Dermatitis (SCORAD).;Pruritus severity. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Visual Analog Scale (VAS).;Skin-related quality of life. Timepoint: Data were collected and analyzed at baseline and after two weeks and four weeks of treatment. Method of measurement: Assessed using the Dermatologic Life Quality Index (DLQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Amini

Shiraz University of Medical Sciences

amini.elham9170@yahoo.com+98 71 3628 0318

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026